Self-reported Medical and Nonmedical Cannabis Use Among Pregnant Women in the United States

decreased from 87% (95% CI, 84%-89%) for 2017 to 74% (95% CI, 71%-77%) for 2018 to 58% (95% CI, 55%-61%) for 2019 (P < .001).Discussion | The proportion of Part D plans requiring prior authorization for buprenorphine products decreased between 2017 and 2019, with a steep decline between 2018 and 2019 that was associated with policy changes made by the FDA and CMS.The 2017 to 2018 reduction that occurred prior to the FDA and CMS policy announcements may have been stimulated by other efforts such as the New York attorney general's investigation of health plans for parity violations related to their use of prior authorization for opioid use disorder medications.6 The data are important because Medicare policy is often viewed as a standard that is subsequently adopted by private health plans and Medicaid.This study is limited in that it does not analyze the effect of prior authorization policies on buprenorphine use and subsequent outcomes.Additional research regarding the benefits of requiring prior authorization compared with the risk of imposing barriers to opioid use disorder treatment is needed.